-
Mashup Score: 0
Researchers sought to determine the effect of chronic graft-versus-host disease on late effects after HCT in pediatric cancer survivors.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1XXVI Congresso SBTMO 2022 - 2 year(s) ago
É com grande satisfação que apresentamos a vocês o XXVI Congresso da Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea (SBTMO 2022) – Novos Tempos, Novos Horizontes!
Source: XXVI Congresso SBTMO 2022Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join Drs. Mary Flowers, Stella Davies, and Corey Cutler at SBMTO Congress this August! They will represent ASTCT in the 4th Joint Session of ASTCT/SBTMO, Meet-the-Professor, #GVHD Roundtable, #cGVHD Course and more. Check out the agenda and register today: https://t.co/AbP6vyQZ6t https://t.co/c7rWBBwHZz
-
-
Mashup Score: 1ASTCT Learning Center: GVHD - 2 year(s) ago
GVHD Contains 1 Component(s)Join Dr. Kirk R. Schultz from the University of British Columbia as he discusses new and emerging therapies in cGvHD. In this 20 min. presentation, he focuses on the future directions of treatment for cGvHD, including the idea of synergistic therapy and how biomarkers may be used to personalize…
Source: learn.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Although #cGVHD is a common complication following stem #celltransplantation, managing the highly morbid forms of the disease is a significant challenge. This series provides the current science, the prevailing guidance and more. Access for free: #GVHD https://t.co/VBxACT5YAj https://t.co/hYzOXpQ8Bl
-
-
Mashup Score: 1
Patients with chronic graft-versus-host disease who received a full series of the SARS-CoV-2 vaccine showed varied immune responses, regardless of their baseline characteristics.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with chronic graft-versus-host disease who received a full series of the SARS-CoV-2 vaccine showed varied immune responses, regardless of their baseline characteristics. #cGVHD #oncology https://t.co/VRhGOcr7OQ
-
-
Mashup Score: 1BET-Bromodomain and EZH2 Inhibitor Treated Chronic GVHD Mice - 2 year(s) ago
Zaiken MC, Flynn R, Paz KG, et al. BET-Bromodomain and EZH2 Inhibitor Treated Chronic GVHD Mice Have Blunted Germinal Centers With Distinct Transcriptomes. Blood. 2022; (doi: 10.1182/blood.2021014557). Anti-cancer enzyme inhibitors disrupt the germinal center (GC) in mice that is necessary for chronic graft-versus-host disease (cGVHD) to develop after allogeneic hematopoietic stem cell…
Source: ASTCT NucleusCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“Anti-cancer enzyme inhibitors disrupt the germinal center #GC in mice that is necessary for chronic graft-versus-host disease #cGVHD to develop after allogeneic hematopoietic stem cell transplant, making them promising therapeutic targets.” https://t.co/IJWQuEgu3s https://t.co/V6TOOTkciC
-
-
Mashup Score: 2
Based on an interim analysis of a randomized phase 2 trial, use of topical ruxolitinib showed reduced body surface area of chronic graft-versus-host disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ruxolitinib in the form of a topical cream has demonstrated positive outcomes for patients with cutaneous chronic graft-vs-host disease. #TCT22 #cGVHD https://t.co/JMEAdVZOxQ
-
-
Mashup Score: 1
The majority of patients treated in a phase 1 trial of belimumab used as chronic graft-vs-host-disease prophylaxis showed no evidence of the disease after 20 months of follow-up.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study results show that belimumab may aid in the prevention of chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation. #cGVHD #oncology #TCT22 https://t.co/gqPwKSsmPc
-
-
Mashup Score: 0Less GVHD and Prednisone Use With Abatacept Seen Post SCT - 2 year(s) ago
In a phase 2 trial, rates of steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant were reduced.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a phase 2 clinical trial, both reduction in steroid-refractory chronic graft versus host disease, and prednisone use were observed among patients treated with abatacept following stem cell transplant. #cGVHD #gvhd #oncology https://t.co/E9QWpz4MIA
-
-
Mashup Score: 0Introduction: A 58-Year-Old Man With Moderate Steroid-Refractory cGVHD and Risk Factors for cGVHD - 2 year(s) ago
Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease after a stem cell transplant, and briefly reviews risk factors for developing cGVHD. #cGVHD @MedStarGUH https://t.co/EYegEKUibR
-
-
Mashup Score: 3Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Belumosudil is an oral rho-associated, coiled-coil–containing protein kinase #inhibitor which inhibits ROCK2, but also ROCK1 to a lesser extent. It is approved for patients with chronic graft-versus-host disease (#cGVHD). Read more: https://t.co/IQRIUHfNuN #pharmonc https://t.co/fFl7GXrGeW
-
A study evaluating late effects of #alloHCT on pediatric survivors of cancer suggests that chronic graft-versus-host disease is associated with nonmalignant effects, but not with subsequent neoplasms. With @ASTCT_Journal. https://t.co/Lq9mWt5zej #cGVHD #PediatricCancer